Allon broadens intellectual property with new patent
Allon Therapeutics Inc. announced that it has been granted a patent relating to the use of Allon’s drug candidates, including lead drug candidate davunetide and pipeline product AL-309, to treat certain types of peripheral neurotoxicity. This new Australian patent strengthens Allon’s intellectual property estate which includes 15 patent families, 61 issued patents and over 30 pending applications worldwide.
Dr. Alistair Stewart, Allon’s Vice President of Commercial Research, said this new patent highlights Allon’s commitment to provide global patent coverage of its technology platform for neurodegenerative disease.
“In preclinical studies, AL-309 showed promising results in a model of chemotherapy-induced neuropathy. Although this technology is early-stage, it represents a large commercial opportunity in the $3 billion peripheral neuropathic pain market,” Stewart explains. “This new patent adds value to our extensive intellectual property estate. “
Allon previously presented preclinical data at the 2009 Society for Neurosciences meeting, demonstrating the potential of AL-309 in chemotherapy-induced neuropathy. AL-309 showed neuroprotective activity and reduction of pain symptoms in a preclinical model of oxaliplatin-induced neuropathy.
The issued patent contains claims relating to the method of using AL-209, AL-309 and various derivatives alone or in combination with Allon’s lead product candidate davunetide to treat peripheral neurotoxicity caused by drugs used to treat cancer, multiple sclerosis, gout, arthritis, Behcet’s disease, psychiatric disorders, immunosuppression and infectious disease.
Other news from the department research and development
